Key facts
- Somaticode’s last known valuation is $3.0M.
- It has raised $150K.
- Notable investors include Right Side Capital Management.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Somaticode
- ·The full record, as it builds
Funding rounds
No funding rounds for Somaticode are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Somaticode
Developer of a health technology platform designed to assess genetic and biochemical factors influencing mood and behavior. The company's platform provides saliva-based testing for methylation pathways, generates personalized supplement recommendations, integrates DNA analysis, and connects users with certified practitioners for lifestyle guidance, enabling individuals and families with conditions such as autism, anxiety, depression, and mood disorders to understand biochemical balance, adopt targeted adjustments, and improve daily functioning.
- Sector
- Healthcare
- HQ
- Orem, UT, United States
- Founded
- 2016
- Employees
- 3
- Website
- somaticode.com/
- Ownership
- Privately Held (backing)
Somaticode doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Somaticode shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Somaticode in its N-PORT filings yet. We sweep new filings monthly.